Brandes International ETF BINV 深 沪
已收盘 08-01 16:00:00 美东时间
35.74
-0.053
-0.15%
华盛通- 最 高35.74
- 今 开35.73
- 成交量 2.92万股
- 最 低 35.5302
- 昨 收 35.7926
- 总市值 2.52亿
- 52周最高 37.01
- 市盈率 静 --
- 换手率 0.41%
- 52周最低 28.4314
- 委 比 0.00%
- 总股本 705.00万
- 历史最高 37.01
- 量 比 0.64
- 振 幅 0.59%
- 历史最低 23.3506
- 每 手 1
- 风险率 2.21%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BioInvent Showcases BI-1910 Development at PAGE 2025
BioInvent International AB ( ($SE:BINV) ) has issued an announcement. BioInvent...
06-04 14:33
XOMA Royalty purchases mezagitamab royalty rights from BioInvent International for $30M
XOMA Royalty (NASDAQ:XOMA) and BioInvent International (BINV) said on Tuesday that XOMA Royalty has purchased the future mezagitamab royalty and milestone interests held by BioInvent for USD $20 mill...
05-27 20:47
XOMA Royalty Purchases Mezagitamab Royalty and Milestone Rights Held by BioInvent International for up to USD $30 Million
XOMA Royalty Corporation purchased BioInvent International's future royalty and milestone interests in mezagitamab for $20 million, with a potential total of $30 million. The transaction enhances XOMA's portfolio and provides BioInvent non-dilutive capital to advance its pipeline. Mezagitamab, a Phase 3 anti-CD38 antibody, aims for best-in-class status in cancer immunotherapy.
05-27 12:01
CASI Pharmaceuticals Report Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma In China
CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and pharmaceutical products, and BioInvent International AB
2024-03-05 20:04
